Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down"
In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 week...
Gespeichert in:
| Veröffentlicht in: | The Journal of asthma 2008-01, Vol.45 (8), p.681-687 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 687 |
|---|---|
| container_issue | 8 |
| container_start_page | 681 |
| container_title | The Journal of asthma |
| container_volume | 45 |
| creator | Koenig, Steven M. Ostrom, Nancy Pearlman, David Waitkus-Edwards, Kelli Yancey, Steven Prillaman, Barbara A. Dorinsky, Paul |
| description | In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS. |
| doi_str_mv | 10.1080/02770900802168695 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_18951261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69706929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-2175ee605bc982aa69816d500c9bb1446cd2f35458771252902e32726a7dceaa3</originalsourceid><addsrcrecordid>eNp9kEGL1DAUx4Mo7rj6AbxI2IO3Oi9pkzboZZlxVVhQHMVjSdM3OxnbpJukLnvxs5thBkSEPb3w8v_9efwIecngDYMGlsDrGhTkJ2eykUo8IgsmSl5UJZSPyeLwX-RAeUaexbgHyAuQT8kZa5RgXLIF-b3GhMH6oJP1jlpHL2PajZquvEvBD_THDh3dzN0eTYr0Kxq0v6y7oVfDnKzR0TukX4KfMq0TLjd6GA-NmWQASwF0NDd0bePPOVIdkF5sEk4T9sXa37mL5-TJVg8RX5zmOfl-9f7b6mNx_fnDp9XldWGqGlLBWS0QJYjOqIZrLVXDZC8AjOo6VlXS9Hxbiko0dc244Ao4lrzmUte9Qa3Lc_L62DsFfztjTO1oo8Fh0A79HFupshjFVQ6yY9AEH2PAbTsFO-pw3zJoD9Lb_6Rn5tWpfO5G7P8SJ8s58O4YsG7rw6jvfBj6Nun7wYdt0M7Y2JYP9b_9B9-hHtLOZJvt3s_BZXEPXPcHuxyhMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69706929</pqid></control><display><type>article</type><title>Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down"</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Koenig, Steven M. ; Ostrom, Nancy ; Pearlman, David ; Waitkus-Edwards, Kelli ; Yancey, Steven ; Prillaman, Barbara A. ; Dorinsky, Paul</creator><creatorcontrib>Koenig, Steven M. ; Ostrom, Nancy ; Pearlman, David ; Waitkus-Edwards, Kelli ; Yancey, Steven ; Prillaman, Barbara A. ; Dorinsky, Paul</creatorcontrib><description>In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.</description><identifier>ISSN: 0277-0903</identifier><identifier>EISSN: 1532-4303</identifier><identifier>DOI: 10.1080/02770900802168695</identifier><identifier>PMID: 18951261</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject><![CDATA[Acetates - administration & dosage ; Albuterol - administration & dosage ; Albuterol - analogs & derivatives ; Androstadienes - administration & dosage ; Anti-Asthmatic Agents - administration & dosage ; asthma ; Asthma - drug therapy ; Asthma - physiopathology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Combinations ; Female ; Fluticasone ; fluticasone propionate ; Fluticasone-Salmeterol Drug Combination ; Forced Expiratory Flow Rates - drug effects ; Humans ; Kaplan-Meier Estimate ; Male ; montelukast ; Patient Satisfaction ; Peak Expiratory Flow Rate - drug effects ; Quinolines - administration & dosage ; salmeterol ; Salmeterol Xinafoate ; Surveys and Questionnaires]]></subject><ispartof>The Journal of asthma, 2008-01, Vol.45 (8), p.681-687</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-2175ee605bc982aa69816d500c9bb1446cd2f35458771252902e32726a7dceaa3</citedby><cites>FETCH-LOGICAL-c470t-2175ee605bc982aa69816d500c9bb1446cd2f35458771252902e32726a7dceaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/02770900802168695$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/02770900802168695$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,59626,59732,60415,60521,61200,61235,61381,61416</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18951261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koenig, Steven M.</creatorcontrib><creatorcontrib>Ostrom, Nancy</creatorcontrib><creatorcontrib>Pearlman, David</creatorcontrib><creatorcontrib>Waitkus-Edwards, Kelli</creatorcontrib><creatorcontrib>Yancey, Steven</creatorcontrib><creatorcontrib>Prillaman, Barbara A.</creatorcontrib><creatorcontrib>Dorinsky, Paul</creatorcontrib><title>Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down"</title><title>The Journal of asthma</title><addtitle>J Asthma</addtitle><description>In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.</description><subject>Acetates - administration & dosage</subject><subject>Albuterol - administration & dosage</subject><subject>Albuterol - analogs & derivatives</subject><subject>Androstadienes - administration & dosage</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Fluticasone</subject><subject>fluticasone propionate</subject><subject>Fluticasone-Salmeterol Drug Combination</subject><subject>Forced Expiratory Flow Rates - drug effects</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>montelukast</subject><subject>Patient Satisfaction</subject><subject>Peak Expiratory Flow Rate - drug effects</subject><subject>Quinolines - administration & dosage</subject><subject>salmeterol</subject><subject>Salmeterol Xinafoate</subject><subject>Surveys and Questionnaires</subject><issn>0277-0903</issn><issn>1532-4303</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEGL1DAUx4Mo7rj6AbxI2IO3Oi9pkzboZZlxVVhQHMVjSdM3OxnbpJukLnvxs5thBkSEPb3w8v_9efwIecngDYMGlsDrGhTkJ2eykUo8IgsmSl5UJZSPyeLwX-RAeUaexbgHyAuQT8kZa5RgXLIF-b3GhMH6oJP1jlpHL2PajZquvEvBD_THDh3dzN0eTYr0Kxq0v6y7oVfDnKzR0TukX4KfMq0TLjd6GA-NmWQASwF0NDd0bePPOVIdkF5sEk4T9sXa37mL5-TJVg8RX5zmOfl-9f7b6mNx_fnDp9XldWGqGlLBWS0QJYjOqIZrLVXDZC8AjOo6VlXS9Hxbiko0dc244Ao4lrzmUte9Qa3Lc_L62DsFfztjTO1oo8Fh0A79HFupshjFVQ6yY9AEH2PAbTsFO-pw3zJoD9Lb_6Rn5tWpfO5G7P8SJ8s58O4YsG7rw6jvfBj6Nun7wYdt0M7Y2JYP9b_9B9-hHtLOZJvt3s_BZXEPXPcHuxyhMA</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Koenig, Steven M.</creator><creator>Ostrom, Nancy</creator><creator>Pearlman, David</creator><creator>Waitkus-Edwards, Kelli</creator><creator>Yancey, Steven</creator><creator>Prillaman, Barbara A.</creator><creator>Dorinsky, Paul</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down"</title><author>Koenig, Steven M. ; Ostrom, Nancy ; Pearlman, David ; Waitkus-Edwards, Kelli ; Yancey, Steven ; Prillaman, Barbara A. ; Dorinsky, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-2175ee605bc982aa69816d500c9bb1446cd2f35458771252902e32726a7dceaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetates - administration & dosage</topic><topic>Albuterol - administration & dosage</topic><topic>Albuterol - analogs & derivatives</topic><topic>Androstadienes - administration & dosage</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Fluticasone</topic><topic>fluticasone propionate</topic><topic>Fluticasone-Salmeterol Drug Combination</topic><topic>Forced Expiratory Flow Rates - drug effects</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>montelukast</topic><topic>Patient Satisfaction</topic><topic>Peak Expiratory Flow Rate - drug effects</topic><topic>Quinolines - administration & dosage</topic><topic>salmeterol</topic><topic>Salmeterol Xinafoate</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koenig, Steven M.</creatorcontrib><creatorcontrib>Ostrom, Nancy</creatorcontrib><creatorcontrib>Pearlman, David</creatorcontrib><creatorcontrib>Waitkus-Edwards, Kelli</creatorcontrib><creatorcontrib>Yancey, Steven</creatorcontrib><creatorcontrib>Prillaman, Barbara A.</creatorcontrib><creatorcontrib>Dorinsky, Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of asthma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koenig, Steven M.</au><au>Ostrom, Nancy</au><au>Pearlman, David</au><au>Waitkus-Edwards, Kelli</au><au>Yancey, Steven</au><au>Prillaman, Barbara A.</au><au>Dorinsky, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down"</atitle><jtitle>The Journal of asthma</jtitle><addtitle>J Asthma</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>45</volume><issue>8</issue><spage>681</spage><epage>687</epage><pages>681-687</pages><issn>0277-0903</issn><eissn>1532-4303</eissn><abstract>In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>18951261</pmid><doi>10.1080/02770900802168695</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0903 |
| ispartof | The Journal of asthma, 2008-01, Vol.45 (8), p.681-687 |
| issn | 0277-0903 1532-4303 |
| language | eng |
| recordid | cdi_pubmed_primary_18951261 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Acetates - administration & dosage Albuterol - administration & dosage Albuterol - analogs & derivatives Androstadienes - administration & dosage Anti-Asthmatic Agents - administration & dosage asthma Asthma - drug therapy Asthma - physiopathology Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Female Fluticasone fluticasone propionate Fluticasone-Salmeterol Drug Combination Forced Expiratory Flow Rates - drug effects Humans Kaplan-Meier Estimate Male montelukast Patient Satisfaction Peak Expiratory Flow Rate - drug effects Quinolines - administration & dosage salmeterol Salmeterol Xinafoate Surveys and Questionnaires |
| title | Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are "Stepped-Down" |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T07%3A31%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deterioration%20in%20Asthma%20Control%20When%20Subjects%20Receiving%20Fluticasone%20Propionate/Salmeterol%20100/50%20mcg%20Diskus%20are%20%22Stepped-Down%22&rft.jtitle=The%20Journal%20of%20asthma&rft.au=Koenig,%20Steven%20M.&rft.date=2008-01-01&rft.volume=45&rft.issue=8&rft.spage=681&rft.epage=687&rft.pages=681-687&rft.issn=0277-0903&rft.eissn=1532-4303&rft_id=info:doi/10.1080/02770900802168695&rft_dat=%3Cproquest_pubme%3E69706929%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69706929&rft_id=info:pmid/18951261&rfr_iscdi=true |